Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06175000 · ClinicalTrials.gov registry record · Phase 2

Maintenance Obinutuzumab in Treating Patients With Central Nervous System Lymphoma Who Have Achieved a Complete or Partial Response

A Phase 2 study of Primary Central Nervous System Lymphoma, sponsored by Providence Health & Services.

Recruiting
Registry status
Phase 2
Development phase
28
Enrollment target
7
Study locations

NCT06175000 is a Phase 2 study of Primary Central Nervous System Lymphoma that is actively recruiting participants, run by Providence Health & Services. The registered enrollment target is 28 participants, below the 50-participant average among 12 other Primary Central Nervous System Lymphoma trials with a reported enrollment target (44% lower). The trial reports 7 study locations across 7 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06175000, a Phase 2 study of Primary Central Nervous System Lymphoma, is actively recruiting participants, sponsored by Providence Health & Services.

RECRUITING
Registry status
Phase 2
Development phase
28 participants
Enrollment target
7
Study locations

Study Summary

This randomized phase II trial studies how well obinutuzumab works as maintenance treatment in patients with central nervous system lymphoma who have achieved the disappearance of all signs of cancer in response to treatment (complete response) or a decrease in the size of a tumor, or in the extent of cancer in the body, in response to treatment (partial response). Immunotherapy with obinutuzumab, may induce changes in body's immune system and may interfere with the ability of tumor cells to grow and spread.

Conditions Studied

Primary Central Nervous System Lymphoma

Interventions

  • PROCEDURE Cognitive Assessment
  • BIOLOGICAL Obinutuzumab
  • OTHER Quality of Life Assessment

Study Locations (7)

New York

  • Memorial Sloan Kettering Cancer Center - New York

Ohio

  • Cleveland Clinic - Cleveland

Oregon

  • Providence Health & Services; Providence Neurological Specialties - Portland

Pennsylvania

  • Pennsylvania State University - Hershey

Vermont

  • University of Vermont - Burlington

Virginia

  • University of Virginia - Charlottesville

Washington

  • Ivy Center for Advanced Brain Tumor Treatment; Swedish Neuroscience Institute - Seattle

Trial Details

FieldValue
Enrollment Target 28 participants
Start Date 2024-03-13
Est. Completion 2029-09-15
Phase Phase 2

Sponsor

Providence Health & Services

69 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06175000

The ClinicalTrials.gov registry entry for NCT06175000 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 28 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 50-participant average among 12 other Primary Central Nervous System Lymphoma trials with a reported enrollment target (44% lower). The listed sponsor is Providence Health & Services, which has 69 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Primary Central Nervous System Lymphoma appearing as the primary indexed condition, and to 3 interventions - of which Cognitive Assessment is the first listed.

NCT06175000 reports 7 study locations spanning 7 distinct geographic areas - top geographies include New York, Ohio, Oregon.

Frequently Asked Questions

What is clinical trial NCT06175000 about?

NCT06175000 is a clinical study titled "Maintenance Obinutuzumab in Treating Patients With Central Nervous System Lymphoma Who Have Achieved a Complete or Partial Response". This randomized phase II trial studies how well obinutuzumab works as maintenance treatment in patients with central nervous system lymphoma who have achieved the disappearance of all signs of cancer in response to treatment (complete response) or a decrease in the size of a tumor, or in the extent ...

What is the current status of trial NCT06175000?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 28 participants. The study started on 2024-03-13. Estimated completion is 2029-09-15.

What conditions does trial NCT06175000 study?

This clinical trial studies the following conditions: Primary Central Nervous System Lymphoma.

What interventions are being tested in trial NCT06175000?

The interventions under investigation include: Cognitive Assessment (PROCEDURE), Obinutuzumab (BIOLOGICAL), Quality of Life Assessment (OTHER).

Who is sponsoring clinical trial NCT06175000?

This trial is sponsored by Providence Health & Services, which has 69 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06175000 being conducted?

This trial has 7 study locations across New York, Ohio, Oregon, Pennsylvania, Vermont. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Primary Central Nervous System Lymphoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Primary Central Nervous System Lymphoma

All registered trials for this condition

New York

All trials with a study site in New York

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.